Cahill Advises Nektar Therapeutics in Agreement to Sell CIMZIA® and MIRCERA® Royalties to Royalty Pharma for $124 Million
Date: 02/29/12
Cahill advised biopharmaceutical company Nektar Therapeutics in connection with its agreement to sell to Royalty Pharma its royalties on future sales of CIMZIA®, a drug used to treat Crohn’s disease, under Nektar's agreement with UCB Pharma, and MIRCERA®, a drug used to treat anemia, under Nektar's agreement with Roche. In consideration for the sale, Royalty Pharma will pay Nektar an aggregate cash payment of $124.0 million. Nektar turned to Cahill, in part, because of its unique and extensive experience in structuring and executing royalty backed transactions.